Tag: rna targeting small molecules therapeutics market forecast

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global RNA Targeting Small Molecules Therapeutics Market Valued at Present and by 2029?

The market size for RNA targeting small molecules therapies has seen substantial growth in the last few years. The market is projected to increase from $6.1 billion in 2024 to $7.83 billion in 2025, with a compound annual growth rate (CAGR) of 28.3%. The historical growth is linked to factors such as drug discovery and development, the increasing incidence of RNA-related illnesses, funding from government and private entities, interest from the pharmaceutical industry, and successful cases with RNA therapeutics.

In the coming years, the market size for RNA targeting small molecules therapeutics is anticipated to experience an explosive growth. It is predicted to elevate to “$21.95 billion by 2029 with a compound annual growth rate (CAGR) of 29.4%. This anticipated growth in the projected period can be ascribed to factors such as precision medicine and personalized therapies, an increase in the identification of RNA biomarkers, an expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. Some significant trends for the forecasted period encompass progress in screening technologies, dominance of antisense oligonucleotides, RNA binders of small molecules, RNA therapeutics application in neurological disorders, and gene editing utilizing the CRISPR-Cas9 technique.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

#What Drivers Are Influencing Growth In The RNA Targeting Small Molecules Therapeutics Market?

The rise in cancer instances is predicted to accelerate the growth of the RNA-targeting small molecule therapeutics market. Cancer encompasses a variety of diseases that can arise in almost any organ or tissue when abnormal cells multiply uncontrollably, surpassing their usual constraints and either infiltrating other organs or intruding into adjacent body components. RNA-targeting small molecules, which are designed and studied to selectively target RNA sequences associated with cancer, are used in cancer treatment. For example, research issued by the American Cancer Society, a health organization based in the US, stated in January 2022 that approximately 609,360 cancer-related deaths and 1.9 million new cancer cases are predicted in the US in 2022, averaging about 1,670 deaths daily. As a result, the RNA-targeting small molecule therapeutics market’s growth is being fueled by the escalating number of cancer cases.

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Notable Trends Are Shaping The Direction Of The RNA Targeting Small Molecules Therapeutics Market?

The increasing tendency towards strategic alliances is a prime trend observed in the RNA-targeting small molecule therapeutics market. Mainstream firms involved in this market are establishing partnerships to foster novel relationship dynamics that facilitate inventive product development. One example is the collaboration in June 2022 between Otsuka Pharmaceutical Co. Ltd., a Japanese pharmaceutical manufacturer, and xFOREST Therapeutics Co. Ltd., a fellow Japan-based drug discovery platform creator. Under this partnership, Otsuka will utilize the Forest technology provided by xFOREST to enhance its research in systemic small-molecule medication discovery, particularly in RNA structures. Moreover, in April 2024, Ipsen, a French biopharmaceutical enterprise, formed a partnership with Skyhawk Therapeutics, a clinical-stage biotechnology company based in the US which is known for its RNA-targeting small molecule therapeutics. The objective of this collaboration was to develop RNA-targeting small molecule medicines for infrequent neurological disorders and amalgamate diverse data sets to create and establish small molecules that have the ability to modulate RNA.

Which Companies Play A Key Role In The Development Of The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

What Are The Key Regional Developments Shaping The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global RNA Targeting Small Molecules Therapeutics Market Valued at Present and by 2029?

The market size for RNA targeting small molecules therapies has seen substantial growth in the last few years. The market is projected to increase from $6.1 billion in 2024 to $7.83 billion in 2025, with a compound annual growth rate (CAGR) of 28.3%. The historical growth is linked to factors such as drug discovery and development, the increasing incidence of RNA-related illnesses, funding from government and private entities, interest from the pharmaceutical industry, and successful cases with RNA therapeutics.

In the coming years, the market size for RNA targeting small molecules therapeutics is anticipated to experience an explosive growth. It is predicted to elevate to “$21.95 billion by 2029 with a compound annual growth rate (CAGR) of 29.4%. This anticipated growth in the projected period can be ascribed to factors such as precision medicine and personalized therapies, an increase in the identification of RNA biomarkers, an expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. Some significant trends for the forecasted period encompass progress in screening technologies, dominance of antisense oligonucleotides, RNA binders of small molecules, RNA therapeutics application in neurological disorders, and gene editing utilizing the CRISPR-Cas9 technique.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

#What Drivers Are Influencing Growth In The RNA Targeting Small Molecules Therapeutics Market?

The rise in cancer instances is predicted to accelerate the growth of the RNA-targeting small molecule therapeutics market. Cancer encompasses a variety of diseases that can arise in almost any organ or tissue when abnormal cells multiply uncontrollably, surpassing their usual constraints and either infiltrating other organs or intruding into adjacent body components. RNA-targeting small molecules, which are designed and studied to selectively target RNA sequences associated with cancer, are used in cancer treatment. For example, research issued by the American Cancer Society, a health organization based in the US, stated in January 2022 that approximately 609,360 cancer-related deaths and 1.9 million new cancer cases are predicted in the US in 2022, averaging about 1,670 deaths daily. As a result, the RNA-targeting small molecule therapeutics market’s growth is being fueled by the escalating number of cancer cases.

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Notable Trends Are Shaping The Direction Of The RNA Targeting Small Molecules Therapeutics Market?

The increasing tendency towards strategic alliances is a prime trend observed in the RNA-targeting small molecule therapeutics market. Mainstream firms involved in this market are establishing partnerships to foster novel relationship dynamics that facilitate inventive product development. One example is the collaboration in June 2022 between Otsuka Pharmaceutical Co. Ltd., a Japanese pharmaceutical manufacturer, and xFOREST Therapeutics Co. Ltd., a fellow Japan-based drug discovery platform creator. Under this partnership, Otsuka will utilize the Forest technology provided by xFOREST to enhance its research in systemic small-molecule medication discovery, particularly in RNA structures. Moreover, in April 2024, Ipsen, a French biopharmaceutical enterprise, formed a partnership with Skyhawk Therapeutics, a clinical-stage biotechnology company based in the US which is known for its RNA-targeting small molecule therapeutics. The objective of this collaboration was to develop RNA-targeting small molecule medicines for infrequent neurological disorders and amalgamate diverse data sets to create and establish small molecules that have the ability to modulate RNA.

Which Companies Play A Key Role In The Development Of The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

What Are The Key Regional Developments Shaping The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the RNA Targeting Small Molecules Therapeutics Market Heading Into 2029?

The market size of RNA targeting small molecules therapeutics has witnessed a substantial surge in the past few years. There’s an expected leap in its value from $6.1 billion in 2024 to a whopping $7.83 billion in 2025 showing a compound annual growth rate (CAGR) of 28.3%. The phenomenal growth in the market during this historical period can be credited to the progress in drug discovery and development, an increase in RNA-related diseases, funding provided by the government and private bodies, vested interest of the pharmaceutical industry, and the previous successes in the field of RNA therapeutics.

The market size for RNA targeting small molecules therapeutics is anticipated to witness substantial growth in the coming years. It is projected to reach $21.95 billion by 2029, seeing a compound annual growth rate (CAGR) of 29.4%. Factors contributing to this growth in the forecast period include precision medicine and personalized therapies, increase in RNA biomarker identification, the expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. In the forecast period, significant trends include advancements in screening technologies, the dominance of antisense oligonucleotides, small molecule RNA binders, the use of RNA therapeutics in treating neurological disorders, and gene editing with crispr-cas9.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Which Factors Are Pushing The RNA Targeting Small Molecules Therapeutics Market Forward?

The growth of the RNA-targeting small molecule therapeutics market is anticipated to be spurred by the escalating occurrence of cancer cases. Cancer comprises a range of diseases that may arise in virtually any organ or tissue when rogue cells grow without restriction, breach their normal limits, and either disseminate to other organs or infiltrate adjacent body parts. RNA-targeting small molecules, specifically designed and examined for selectively targeting RNA molecules tied to cancer, are used to treat this disease. A notable example is a study published by the American Cancer Society, a health organization based in the US, in January 2022. The report predicted approximately 609,360 deaths and 1.9 million fresh cancer cases in the US in 2022, which equates to around 1,670 deaths per day. As such, the proliferating count of cancer cases is seen as a key driver for the expansion of the RNA-targeting small molecule therapeutics market.

Which Segment Held The Largest Share In The RNA Targeting Small Molecules Therapeutics Market In 2025?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

How Are Key Trends Driving Expansion In The RNA Targeting Small Molecules Therapeutics Industry?

One major trend that is gaining considerable traction in the retinal biologics market is product innovation. Major players in this market are focusing on designing novel products as a strategy to solidify their market position and obtain a competitive edge. For example, in May 2023, F. Hoffmann-La Roche Ltd., a Swiss healthcare organization, received approval from the U.S. Food and Drug Administration for its supplemental biologics license application (sBLA) for Vabysmo (faricimab). This approval was granted for the treatment of macular edema following retinal vein occlusion (RVO), based on the results of two Phase III trials. These trials demonstrated early and substantial visual improvement in patients using Vabysmo, achieving its primary operative endpoint of being as effective as aflibercept. Vabysmo stands as the inaugural bispecific antibody approved for ocular use, particularly for treating neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Subsequent research showed a lack of blood vessel leakage in the retina in patients using Vabysmo compared to those using aflibercept.

Which Organizations Are Driving Progress In The RNA Targeting Small Molecules Therapeutics Industry?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The RNA Targeting Small Molecules Therapeutics Industry?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the RNA Targeting Small Molecules Therapeutics Market Heading Into 2029?

The market size of RNA targeting small molecules therapeutics has witnessed a substantial surge in the past few years. There’s an expected leap in its value from $6.1 billion in 2024 to a whopping $7.83 billion in 2025 showing a compound annual growth rate (CAGR) of 28.3%. The phenomenal growth in the market during this historical period can be credited to the progress in drug discovery and development, an increase in RNA-related diseases, funding provided by the government and private bodies, vested interest of the pharmaceutical industry, and the previous successes in the field of RNA therapeutics.

The market size for RNA targeting small molecules therapeutics is anticipated to witness substantial growth in the coming years. It is projected to reach $21.95 billion by 2029, seeing a compound annual growth rate (CAGR) of 29.4%. Factors contributing to this growth in the forecast period include precision medicine and personalized therapies, increase in RNA biomarker identification, the expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. In the forecast period, significant trends include advancements in screening technologies, the dominance of antisense oligonucleotides, small molecule RNA binders, the use of RNA therapeutics in treating neurological disorders, and gene editing with crispr-cas9.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Which Factors Are Pushing The RNA Targeting Small Molecules Therapeutics Market Forward?

The growth of the RNA-targeting small molecule therapeutics market is anticipated to be spurred by the escalating occurrence of cancer cases. Cancer comprises a range of diseases that may arise in virtually any organ or tissue when rogue cells grow without restriction, breach their normal limits, and either disseminate to other organs or infiltrate adjacent body parts. RNA-targeting small molecules, specifically designed and examined for selectively targeting RNA molecules tied to cancer, are used to treat this disease. A notable example is a study published by the American Cancer Society, a health organization based in the US, in January 2022. The report predicted approximately 609,360 deaths and 1.9 million fresh cancer cases in the US in 2022, which equates to around 1,670 deaths per day. As such, the proliferating count of cancer cases is seen as a key driver for the expansion of the RNA-targeting small molecule therapeutics market.

Which Segment Held The Largest Share In The RNA Targeting Small Molecules Therapeutics Market In 2025?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

How Are Key Trends Driving Expansion In The RNA Targeting Small Molecules Therapeutics Industry?

One major trend that is gaining considerable traction in the retinal biologics market is product innovation. Major players in this market are focusing on designing novel products as a strategy to solidify their market position and obtain a competitive edge. For example, in May 2023, F. Hoffmann-La Roche Ltd., a Swiss healthcare organization, received approval from the U.S. Food and Drug Administration for its supplemental biologics license application (sBLA) for Vabysmo (faricimab). This approval was granted for the treatment of macular edema following retinal vein occlusion (RVO), based on the results of two Phase III trials. These trials demonstrated early and substantial visual improvement in patients using Vabysmo, achieving its primary operative endpoint of being as effective as aflibercept. Vabysmo stands as the inaugural bispecific antibody approved for ocular use, particularly for treating neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Subsequent research showed a lack of blood vessel leakage in the retina in patients using Vabysmo compared to those using aflibercept.

Which Organizations Are Driving Progress In The RNA Targeting Small Molecules Therapeutics Industry?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The RNA Targeting Small Molecules Therapeutics Industry?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the RNA Targeting Small Molecules Therapeutics Market Heading Into 2029?

The market size of RNA targeting small molecules therapeutics has witnessed a substantial surge in the past few years. There’s an expected leap in its value from $6.1 billion in 2024 to a whopping $7.83 billion in 2025 showing a compound annual growth rate (CAGR) of 28.3%. The phenomenal growth in the market during this historical period can be credited to the progress in drug discovery and development, an increase in RNA-related diseases, funding provided by the government and private bodies, vested interest of the pharmaceutical industry, and the previous successes in the field of RNA therapeutics.

The market size for RNA targeting small molecules therapeutics is anticipated to witness substantial growth in the coming years. It is projected to reach $21.95 billion by 2029, seeing a compound annual growth rate (CAGR) of 29.4%. Factors contributing to this growth in the forecast period include precision medicine and personalized therapies, increase in RNA biomarker identification, the expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. In the forecast period, significant trends include advancements in screening technologies, the dominance of antisense oligonucleotides, small molecule RNA binders, the use of RNA therapeutics in treating neurological disorders, and gene editing with crispr-cas9.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Which Factors Are Pushing The RNA Targeting Small Molecules Therapeutics Market Forward?

The growth of the RNA-targeting small molecule therapeutics market is anticipated to be spurred by the escalating occurrence of cancer cases. Cancer comprises a range of diseases that may arise in virtually any organ or tissue when rogue cells grow without restriction, breach their normal limits, and either disseminate to other organs or infiltrate adjacent body parts. RNA-targeting small molecules, specifically designed and examined for selectively targeting RNA molecules tied to cancer, are used to treat this disease. A notable example is a study published by the American Cancer Society, a health organization based in the US, in January 2022. The report predicted approximately 609,360 deaths and 1.9 million fresh cancer cases in the US in 2022, which equates to around 1,670 deaths per day. As such, the proliferating count of cancer cases is seen as a key driver for the expansion of the RNA-targeting small molecule therapeutics market.

Which Segment Held The Largest Share In The RNA Targeting Small Molecules Therapeutics Market In 2025?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

How Are Key Trends Driving Expansion In The RNA Targeting Small Molecules Therapeutics Industry?

One major trend that is gaining considerable traction in the retinal biologics market is product innovation. Major players in this market are focusing on designing novel products as a strategy to solidify their market position and obtain a competitive edge. For example, in May 2023, F. Hoffmann-La Roche Ltd., a Swiss healthcare organization, received approval from the U.S. Food and Drug Administration for its supplemental biologics license application (sBLA) for Vabysmo (faricimab). This approval was granted for the treatment of macular edema following retinal vein occlusion (RVO), based on the results of two Phase III trials. These trials demonstrated early and substantial visual improvement in patients using Vabysmo, achieving its primary operative endpoint of being as effective as aflibercept. Vabysmo stands as the inaugural bispecific antibody approved for ocular use, particularly for treating neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Subsequent research showed a lack of blood vessel leakage in the retina in patients using Vabysmo compared to those using aflibercept.

Which Organizations Are Driving Progress In The RNA Targeting Small Molecules Therapeutics Industry?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The RNA Targeting Small Molecules Therapeutics Industry?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the RNA Targeting Small Molecules Therapeutics Market Grown from 2024 to 2025?

In recent times, the market for RNA targeting small molecules therapeutics has experienced exponential growth. The market, which was worth $6.1 billion in 2024, is forecasted to expand to $7.87 billion in 2025, with a compound annual growth rate (CAGR) of 28.9%. Factors such as advancements in drug discovery and development, increasing number of RNA-related diseases, both government and private sector funding, interest from the pharmaceutical industry, and successful narratives of RNA therapeutics have contributed to the growth recorded during the historical period.

What Growth Rate Is Anticipated for the RNA Targeting Small Molecules Therapeutics Market in the Coming Years?

The market for RNA targeting small molecule therapeutics is projected to experience an immense expansion in the forthcoming years, with a valuation of $22.36 billion anticipated by 2029, growing at a CAGR of 29.8%. Factors contributing to this surge during the forecast period include the development of precision medicine and individualized treatment approaches, the growing identification of RNA biomarkers, broadening of RNA target spectrum, augmented funding and investments, and applications in rare disease treatments. Further trends predicted for the forecast period are advancements in screening technologies, dominance of antisense oligonucleotides, emergent small molecule RNA binders, RNA therapeutics application for neurological disorders, and gene editing utilizing the crispr-cas9 technique.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Who Are the Leading Companies in the RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

What Are the Key Drivers of the RNA Targeting Small Molecules Therapeutics Market?

The escalating incidence of cancer is predicted to accelerate the growth trajectory of the RNA-targeting small molecule therapeutics market. Cancer encompasses diseases that can originate in almost any tissue or organ when irregular cells multiply beyond control, surpass their typical confines, and spread to other organs or impinge on nearby body parts. The treatment for cancer involves the use of RNA-targeting small molecules that are designed and studied for the purpose of specifically targeting RNA molecules linked with cancer. For instance, studies conducted by the American Cancer Society, a US-based health organization, in January 2022 revealed that there are anticipated to be 609,360 cancer fatalities and 1.9 million fresh cases of cancer in the US in 2022. This approximates to around 1,670 deaths each day. Consequently, the escalating incidence of cancer is stimulating the expansion of the RNA-targeting small molecule therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

What Are the Key Market Segments in the RNA Targeting Small Molecules Therapeutics Industry?

The RNA targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Are the Latest Trends in the RNA Targeting Small Molecules Therapeutics Market?

One of the prevalent trends in the RNA-targeting small molecule therapeutics market is the formation of strategic alliances. Major players in the market are increasingly entering into collaborations to foster a new relationship whereby multiple entities produce innovative items. For example, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturer from Japan, joined forces with xFOREST Therapeutics Co. Ltd., another Japanese company specializing in drug discovery platforms, in June 2022. This partnership allows xFOREST to provide Otsuka with its Forest technology to expedite small-molecule drug discovery research focusing on RNA structures. Furthermore, in April 2024, Ipsen, a biopharmaceutical firm from France, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company offering RNA-targeting small molecule therapeutics. Through this partnership, Ipsen sought to produce RNA-targeting small molecule medicines for rare neurological disorders while employing various data sets to pinpoint and develop small molecules capable of modulating RNA.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

What Are the Key Regional Markets in the RNA Targeting Small Molecules Therapeutics Industry?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12253

This Report Delivers Insight On:

1. How big is the rna targeting small molecules therapeutics market, and how is it changing globally?

2. Who are the major companies in the rna targeting small molecules therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the rna targeting small molecules therapeutics market right now?

4. Which products or customer segments are growing the most in the rna targeting small molecules therapeutics market?

5. What factors are helping or slowing down the growth of the rna targeting small molecules therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the rna targeting small molecules therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the RNA Targeting Small Molecules Therapeutics Market In 2029?

In recent times, the market for RNA targeting small molecules therapeutics has experienced exponential growth. The market, which was worth $6.1 billion in 2024, is forecasted to expand to $7.87 billion in 2025, with a compound annual growth rate (CAGR) of 28.9%. Factors such as advancements in drug discovery and development, increasing number of RNA-related diseases, both government and private sector funding, interest from the pharmaceutical industry, and successful narratives of RNA therapeutics have contributed to the growth recorded during the historical period.

The market for RNA targeting small molecule therapeutics is projected to experience an immense expansion in the forthcoming years, with a valuation of $22.36 billion anticipated by 2029, growing at a CAGR of 29.8%. Factors contributing to this surge during the forecast period include the development of precision medicine and individualized treatment approaches, the growing identification of RNA biomarkers, broadening of RNA target spectrum, augmented funding and investments, and applications in rare disease treatments. Further trends predicted for the forecast period are advancements in screening technologies, dominance of antisense oligonucleotides, emergent small molecule RNA binders, RNA therapeutics application for neurological disorders, and gene editing utilizing the crispr-cas9 technique.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What are the Fundamental Drivers and Innovations Shaping the RNA Targeting Small Molecules Therapeutics Market?

The escalating incidence of cancer is predicted to accelerate the growth trajectory of the RNA-targeting small molecule therapeutics market. Cancer encompasses diseases that can originate in almost any tissue or organ when irregular cells multiply beyond control, surpass their typical confines, and spread to other organs or impinge on nearby body parts. The treatment for cancer involves the use of RNA-targeting small molecules that are designed and studied for the purpose of specifically targeting RNA molecules linked with cancer. For instance, studies conducted by the American Cancer Society, a US-based health organization, in January 2022 revealed that there are anticipated to be 609,360 cancer fatalities and 1.9 million fresh cases of cancer in the US in 2022. This approximates to around 1,670 deaths each day. Consequently, the escalating incidence of cancer is stimulating the expansion of the RNA-targeting small molecule therapeutics market.

How Is the RNA Targeting Small Molecules Therapeutics Market Segmented?

The RNA targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

Which Regions Are Driving the Next Phase of the RNA Targeting Small Molecules Therapeutics Market Growth?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the RNA Targeting Small Molecules Therapeutics Market?

One of the prevalent trends in the RNA-targeting small molecule therapeutics market is the formation of strategic alliances. Major players in the market are increasingly entering into collaborations to foster a new relationship whereby multiple entities produce innovative items. For example, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturer from Japan, joined forces with xFOREST Therapeutics Co. Ltd., another Japanese company specializing in drug discovery platforms, in June 2022. This partnership allows xFOREST to provide Otsuka with its Forest technology to expedite small-molecule drug discovery research focusing on RNA structures. Furthermore, in April 2024, Ipsen, a biopharmaceutical firm from France, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company offering RNA-targeting small molecule therapeutics. Through this partnership, Ipsen sought to produce RNA-targeting small molecule medicines for rare neurological disorders while employing various data sets to pinpoint and develop small molecules capable of modulating RNA.

View the full report here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

How Is the RNA Targeting Small Molecules Therapeutics Market Defined and What Are Its Core Parameters?

RNA-targeting small molecule therapeutics refers to small molecule therapeutics that precisely interact with RNA molecules to modify their function or stability. These treatments treat diseases by employing small-molecule drugs to target disease-causing RNA molecules.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12253

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the RNA Targeting Small Molecules Therapeutics Market?

The surge in cancer incidences is anticipated to stimulate the expansion of the RNA-targeting small molecule therapeutics market. Cancer is a range of diseases that can emerge in just about any organ or tissue when deviant cells multiply uncontrollably, overcoming their typical boundaries and either metastasizing to other organs or encroaching on adjacent body parts. RNA-targeting small molecules are developed and explored for their potential in selectively targeting RNA molecules linked with cancer. For instance, research published by the American Cancer Society, a health organization based in the US, in January 2022, forecasts about 609,360 cancer-related deaths and nearly 1.9 million fresh cancer cases in the US alone for the year 2022. This amounts to an alarming figure of around 1,670 deaths each day. Consequently, the escalating cancer cases are boosting the growth of the RNA-targeting small molecule therapeutics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

How Will the Growth Rate of theRNA Targeting Small Molecules Therapeutics Market Impact Industry Trends by 2034?

Recent years have seen a remarkable expansion in the market size of RNA targeting small molecules therapeutics. Predictions suggest it will increase from $6.1 billion in 2024 to $7.87 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.9%. Factors contributing to this growth during the historic period include progress in drug discovery and development, increased occurrence of RNA-related diseases, funding from both government and private sectors, interest from the pharmaceutical industry, and successful implementations of RNA therapeutics.

Predictions estimate a surging increase in the next few years for the therapeutics market of RNA targeting small molecules, with expectations of a value of $22.36 billion by 2029, marking a compound annual growth rate (CAGR) of 29.8%. Factors contributing to this growth within the predicted timeline include precision medicine along with personalized therapies, an uptick in identification of RNA biomarkers, a wider RNA target spectrum, increased levels of funding and investment, as well as its application in treating rare diseases. Foreseeable trends within this period are progress in screening technologies, the prevalence of antisense oligonucleotides, small molecule RNA binders, RNA therapeutics application in neurological disorders, and gene modification through crispr-cas9.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12253

What New Market Trends Are Reshaping theRNA Targeting Small Molecules Therapeutics Market and Its Opportunities?

The trend of strategic alliances is gaining momentum in the RNA-targeting small molecule therapeutics market. Major firms within the sector are partnering up to foster new collaborative relationships for the creation of breakthrough products. For example, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, entered a partnership with xFOREST Therapeutics Co. Ltd, another Japan-based company specializing in the development of drug discovery platforms, in June 2022. This collaboration will enable xFOREST to provide Forest technology to Otsuka, bolstering systemic small-molecule drug discovery research focused on RNA structures. Additionally, in April 2024, Ipsen, a French biopharmaceutical company, teamed up with Skyhawk Therapeutics, which is a US-based biotechnology company offering RNA-targeting small molecule therapeutics. The goal of this collaboration was for Ipsen to develop RNA-targeting small molecule drugs for uncommon neurological diseases and combine different data sets to pinpoint and develop small molecules capable of modulating RNA.

Who Are the Leading Market Players Fueling Growth in the RNA Targeting Small Molecules Therapeutics Market Trend?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

How is the Global RNA Targeting Small Molecules Therapeutics Market Segemented?

The RNA targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

Which Geographics are Influencing the Growth of the RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal RNA Targeting Small Molecules Therapeutics Maret 2025, By The Business Research Company:

Material Handling Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/material-handling-global-market-report

Overhead Cranes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/overhead-cranes-global-market-report

Tractor Implements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tractor-implements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the RNA Targeting Small Molecules Therapeutics Market: What’s the Expected CAGR for the Next Decade?

The RNA targeting small molecules therapeutics market has witnessed exponential growth in recent years. It is expected to grow from $6.1 billion in 2024 to $7.87 billion in 2025, with a remarkable CAGR of 28.9%. The historical growth can be attributed to advancements in drug discovery and development, the rising prevalence of RNA-related diseases, government and private funding initiatives, increasing interest from the pharmaceutical industry, and the success of RNA therapeutics.

The RNA targeting small molecules therapeutics market is anticipated to grow rapidly, reaching $22.36 billion by 2029 at a CAGR of 29.8%. This growth is driven by the rise of precision medicine and personalized therapies, growing RNA biomarker identification, expansion of the RNA target spectrum, increasing investments and funding, and applications in rare diseases. Key trends include advancements in screening technologies, dominance of antisense oligonucleotides, emergence of small molecule RNA binders, increased RNA therapeutics for neurological disorders, and the application of CRISPR-Cas9 in gene editing.

Which Primary Drivers Are Supporting the Continued Expansion of the rna targeting small molecules therapeutics Market?

The growing incidence of cancer cases is expected to drive the expansion of the RNA-targeting small molecule therapeutics market moving forward. Cancer is a category of diseases that can arise in nearly any organ or tissue when abnormal cells proliferate uncontrollably, transcending their usual limits and invading neighboring areas or spreading to other organs. RNA-targeting small molecules are designed and developed to selectively target RNA molecules linked to cancer for treatment. For example, in January 2022, research from the American Cancer Society estimated that there would be 609,360 cancer deaths and 1.9 million new cancer cases in the US in 2022, averaging about 1,670 deaths per day. Therefore, the increasing number of cancer cases is propelling the RNA-targeting small molecule therapeutics market.

Explore Comprehensive Insights Into The Global RNA Targeting Small Molecules Therapeutics Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Are the Leading Organizations Impacting the RNA Targeting Small Molecules Therapeutics Market’s Growth?

Major companies operating in the RNA targeting small molecules therapeutics market include:

• F. Hoffmann-La Roche Ltd._x000D_

• Bayer AG_x000D_

• Sanofi S.A._x000D_

• AstraZeneca plc_x000D_

• Eli Lilly and Company_x000D_

What Are the Most Prominent Trends Driving Change in the RNA Targeting Small Molecules Therapeutics Market?

Strategic collaborations are shaping the RNA-targeting small molecule therapeutics market. Leading companies are forming partnerships to develop groundbreaking products. For example, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, collaborated with xFOREST Therapeutics Co. Ltd., a Japanese drug discovery platform developer. This partnership enables Otsuka to utilize xFOREST’s Forest technology for small-molecule drug discovery targeting RNA structures. Additionally, in April 2024, Ipsen, a France-based biopharmaceutical company, partnered with Skyhawk Therapeutics, a US-based biotech firm specializing in RNA-targeting therapeutics. This collaboration aims to develop RNA-targeting small molecule drugs for rare neurological disorders, integrating diverse data sets to identify and advance new treatments.

Secure Your Global RNA Targeting Small Molecules Therapeutics Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Segments Play a Crucial Role in the Expansion of the RNA Targeting Small Molecules Therapeutics Market?

The RNA targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Regions Are Leading the Charge in the RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does the Definition of the RNA Targeting Small Molecules Therapeutics Market Include?

RNA-targeting small molecule therapeutics refers to small molecule therapeutics that precisely interact with RNA molecules to modify their function or stability. These treatments treat diseases by employing small-molecule drugs to target disease-causing RNA molecules.

Browse Through More Similar Reports By The Business Research Company:

Material Handling Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/material-handling-global-market-report

Overhead Cranes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/overhead-cranes-global-market-report

Tractor Implements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tractor-implements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: